Highlights in antiviral drug research: Antivirals at the horizon

Medicinal Research Reviews

Volumn 33, Issue 6, 2013, Pages 1215-1248

  Clercq, Erik De ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiarenaviral; Antipicornaviral; CMX001; Cyclopropavir; DUY11; Favipiravir; LJ 001; N MCT; Natural products; PSI 352938; U0126

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; 4' AZIDOCYTIDINE; ACICLOVIR; AMANTADINE; ANTIVIRUS AGENT; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; FAVIPIRAVIR; FOSCARNET; GANCICLOVIR; HOMOISOFLAVONE DERIVATIVE; MERICITABINE; METHANOCARBATHYMIDINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OSELTAMIVIR; PEGINTERFERON ALPHA; PLECONARIL; PSI 7411; RIBAVIRIN; RIMANTADINE; SOFOSBUVIR; SORAFENIB; TRITERPENOID; UNCLASSIFIED DRUG; VALGANCICLOVIR; VALOPICITABINE; VALTORCITABINE; VAPENDAVIR; ZANAMIVIR; BIOLOGICAL PRODUCT;

ADENOVIRUS; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARENAVIRUS INFECTION; ARTICLE; ASTHMA; CHRONIC LUNG DISEASE; COMMON COLD; COMMON VARIABLE IMMUNODEFICIENCY; CYTOMEGALOVIRUS INFECTION; DENGUE; DNA VIRUS; DRUG CONFORMATION; DRUG EFFICACY; ENTEROVIRUS INFECTION; EXTRACELLULAR MATRIX; HEPATITIS C VIRUS; HERPES VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; INFLUENZA; LASSA FEVER; MENINGITIS; MONKEYPOX; MOUSEPOX; NEPHROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POLYOMA VIRUS; POXVIRUS; RHINOVIRUS INFECTION; RNA REPLICATION; RNA VIRUS; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; VIRUS ENVELOPE; VIRUS INHIBITION; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; RESEARCH; VIRUS; VIRUS ENTRY;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; HUMANS; RESEARCH; VIRUS INTERNALIZATION; VIRUSES;

EID: 84874107763     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21256     Document Type: Article

References (205)

1. De Clercq E. The discovery of antiviral agents: Ten different compounds, ten different stories. Med Res Rev 2008;28:929-953.
2. De Clercq E. Antiviral drug discovery: Ten more compounds, and ten more stories (part B). Med Res Rev 2009;29:571-610.
3. De Clercq E. Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies and perspectives. Med Res Rev 2009;29:611-645.
4. De Clercq E. Yet another ten stories on antiviral drug discovery (part D): Paradigms, paradoxes and paraductions. Med Res Rev 2010;30:667-707.
5. De Clercq E. The next ten stories on antiviral drug discovery (part E): Advents, advances and adventures. Med Res Rev 2011;31:118-160.
6. Lam AM, Espiritu C, Bansal S, Steuer HM, Zennou V, Otto MJ, Furman PA. In vitro selection of HCV replicons with reduced sensitivity to PSI-352938, a cyclicphosphate prodrug of β-d-2′-α-F-2′-β-C-methylguanosine. Antiviral Res 2011;90:A22, abstract no 10.
7. Prichard M, Hartline C, Gill R, Bowlin T, James S. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antiviral Res 2011;90:A24, abstract no 17.
8. Cardin R, Bravo F, Clark J, Earwood J, Glazer R, Rahman A, Bernstein D. In vivo efficacy of N-methanocarbathymidine (N-MCT) against herpes simplex virus type 2 in neonatal guinea pigs. Antiviral Res 2011;90:A24-25, abstract no 19.
9. Lanier ER, Painter W, Tippin TK, Anderson M, Lampert BM, Mommeja-Marin H, Trost LC. CMX001 (hexadecyloxypropyl cidofovir) antiviral activity against adenovirus in patients correlates with drug levels and viral sensitivity. Antiviral Res 2011;90:A27-28, abstract no 33.
10. Gowen BB, Mendenhall M, Russell A, Smee DF, Furuta Y. Favipiravir (T-705) treatment of experimental arenaviral infection initiated after the onset of clinical disease. Antiviral Res 2011;90:A52, abstract no 107.
11. Pasquato A, Rochat C, de la Torre JC, Kunz S. Combinatorial anti-arenaviral therapy with the small molecule SKI-1/S1P inhibitor PF-429242 and ribavirin. Antiviral Res 2011;90:A62, abstract no 136.
12. Braun H, Makarov VA, Riabova OB, Komarova ES, Richter M, Wutzler P, Schmidtke M. OBR-5-340-A novel pyrazolo-pyrimidine derivative with strong antiviral activity against Coxsackievirus B3 in vitro and in vivo. Antiviral Res 2011;90:A29; abstract no 39.
13. Richter M, Makarov VA, Riabova OB, Wutzler P, Schmidtke M. Identification and characterization of OBR-5-340 - a novel broad-spectrum anti-human rhinovirus (HRV) inhibitor. Antiviral Res 2011;90:A40, abstract no 73.
14. Vanderlinden E, Vanstreels E, Vermeire K, Daelemans D, Herczegh P, Sztaricskai F, Naesens L. Mechanistic studies on a novel hydrophobic derivative of aglycoristocetin with potent and broad activity against influenza viruses. Antiviral Res 2011;90:A47, abstract 91.
15. Murayama T, Li Y, Yamada R, Sadanari H, Matsubara K, Tuchida Y, Koketsu M, Watanabe K. Inhibition of human cytomegalovirus replication by tricin (4′, 5, 7-trihydroxy-3′, 5′-dimethoxyflavone). Antiviral Res 2011;90:A60, abstract no 131.
16. Droebner K, Ludwig S, Pleschka S, Planz O. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res 2011;90:A32, abstract no 47.
17. Colpitts CC, Ustinov AV, Korshun VA, Schang LM. Rigid amphipathic fusion inhibitors (RAFIs) inhibit infectivity of enveloped viruses by targeting envelope lipids to prevent fusion with cellular membranes. Antiviral Res 2011; A30, abstract no 43.
18. Stuyver LJ, McBrayer TR, Whitaker T, Tharnish PM, Ramesh M, Lostia S, Cartee L, Shi J, Hobbs A, Schinazi RF, Watanabe KA, Otto MJ. Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2′-deoxy-2′-fluorocytidine. Antimicrob Agents Chemother 2004;48:651-654.
19. Clark JL, Hollecker L, Mason JC, Stuyver LJ, Tharnish PM, Lostia S, McBrayer TR, Schinazi RF, Watanabe KA, Otto MJ, Furman PA, Stec WJ, Patterson SE, Pankiewicz KW. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J Med Chem 2005;48:5504-5508.
20. Pierra C, Amador A, Benzaria S, Cretton-Scott E, DAmours M, Mao J, Mathieu S, Moussa A, Bridges EG, Standring DN, Sommadossi JP, Storer R, Gosselin G. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem 2006;49:6614-6620.
21. Klumpp K, Lévêque V, Le Pogam S, Ma H, Jiang WR, Kang H, Granycome C, Singer M, Laxton C, Hang JQ, Sarma K, Smith DB, Heindl D, Hobbs CJ, Merrett JH, Symons J, Cammack N, Martin JA, Devos R, Nájera I. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 2006;281:3793-3799.
22. Smith DB, Martin JA, Klumpp K, Baker SJ, Blomgren PA, Devos R, Granycome C, Hang J, Hobbs CJ, Jiang WR, Laxton C, Le Pogam S, Leveque V, Ma H, Maile G, Merrett JH, Pichota A, Sarma K, Smith M, Swallow S, Symons J, Vesey D, Najera I, Cammack N. Design, synthesis, and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus replication: The discovery of R1479. Bioorg Med Chem Lett 2007;17:2570-2576.
23. Klumpp K, Kalayanov G, Ma H, Le Pogam S, Leveque V, Jiang WR, Inocencio N, De Witte A, Rajyaguru S, Tai E, Chanda S, Irwin MR, Sund C, Winqist A, Maltseva T, Eriksson S, Usova E, Smith M, Alker A, Najera I, Cammack N, Martin JA, Johansson NG, Smith DB. 2′-deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups. J Biol Chem 2008;283:2167-2175.
24. Smith DB, Kalayanov G, Sund C, Winqvist A, Maltseva T, Leveque VJ, Rajyaguru S, Le Pogam S, Najera I, Benkestock K, Zhou XX, Kaiser AC, Maag H, Cammack N, Martin JA, Swallow S, Johansson NG, Klumpp K, Smith M. The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4′-azidocytidine against hepatitis C virus replication: The discovery of 4′-azido-2′-deoxy-2′-fluorocytidine and 4′-azido-2′-dideoxy-2′, 2′-difluorocytidine. J Med Chem 2009;52:2971-2978.
25. Reddy PG, Bao D, Chang W, Chun BK, Du J, Nagarathnam D, Rachakonda S, Ross BS, Zhang HR, Bansal S, Espiritu CL, Keilman M, Lam AM, Niu C, Steuer HM, Furman PA, Otto MJ, Sofia MJ. 2′-deoxy-2′-α-fluoro-2′-β-C-methyl 3′, 5′-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: Discovery of PSI-352938. Bioorg Med Chem Lett 2010;20:7376-7380.
26. Wang P, Chun BK, Rachakonda S, Du J, Khan N, Shi J, Stec W, Cleary D, Ross BS, Sofia MJ. An efficient and diastereoselective synthesis of PSI-6130: A clinically efficacious inhibitor of HCV NS5B polymerase. J Org Chem 2009;74:6819-6824.
27. Murakami E, Bao H, Ramesh M, McBrayer TR, Whitaker T, Micolochick Steuer HM, Schinazi RF, Stuyver LJ, Obikhod A, Otto MJ, Furman PA. Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother 2007;51:503-509.
28. Ma H, Jiang WR, Robledo N, Leveque V, Ali S, Lara-Jaime T, Masjedizadeh M, Smith DB, Cammack N, Klumpp K, Symons J. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J Biol Chem 2007;282:29812-29820.
29. Murakami E, Niu C, Bao H, Micolochick Steuer HM, Whitaker T, Nachman T, Sofia MA, Wang P, Otto MJ, Furman PA. The mechanism of action of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2008;52:458-464.
30. Lam AM, Murakami E, Espiritu C, Steuer HM, Niu C, Keilman M, Bao H, Zennou V, Bourne N, Julander JG, Morrey JD, Smee DF, Frick DN, Heck JA, Wang P, Nagarathnam D, Ross BS, Sofia MJ, Otto MJ, Furman PA. PSI-7851, a pronucleotide of beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 2010;54:3187-3196.
31. Murakami E, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM, Otto MJ, Sofia MJ, Furman PA. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 2010;285:34337-34347.
32. Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HM, Niu C, Otto MJ, Furman PA. Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010;53:7202-7218.
33. Furman PA, Murakami E, Niu C, Lam AM, Espiritu C, Bansal S, Bao H, Tolstykh T, Micolochick Steuer H, Keilman M, Zennou V, Bourne N, Veselenak RL, Chang W, Ross BS, Du J, Otto MJ, Sofia MJ. Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antiviral Res 2011;91:120-132.
34. Reddy PG, Chun BK, Zhang HR, Rachakonda S, Ross BS, Sofia MJ. Stereoselective synthesis of PSI-352938: A β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyl-3′, 5′-cyclic phosphate nucleotide prodrug for the treatment of HCV. J Org Chem 2011;76:3782-3790.
35. Lam AM, Espiritu C, Murakami E, Zennou V, Bansal S, Micolochick Steuer HM, Niu C, Keilman M, Bao H, Bourne N, Veselenak RL, Reddy PG, Chang W, Du J, Nagarathnam D, Sofia MJ, Otto MJ, Furman PA. Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methylguanosine. Antimicrob Agents Chemother 2011;55:2566-2575.
36. Vernachio JH, Bleiman B, Bryant KD, Chamberlain S, Hunley D, Hutchins J, Ames B, Gorovits E, Ganguly B, Hall A, Kolykhalov A, Liu Y, Muhammad J, Raja N, Walters CR, Wang J, Williams K, Patti JM, Henson G, Madela K, Aljarah M, Gilles A, McGuigan C. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2′-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob Agents Chemother 2011;55:1843-1851.
37. McGuigan C, Madela K, Aljarah M, Gilles A, Brancale A, Zonta N, Chamberlain S, Vernachio J, Hutchins J, Hall A, Ames B, Gorovits E, Ganguly B, Kolykhalov A, Wang J, Muhammad J, Patti JM, Henson G. Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg Med Chem Lett 2010;20:4850-4854.
38. Zemlicka J. Methylenecyclopropane analogues of nucleosides as anti-herpes agents. In: De Clercq E, Ed. Advances in Antiviral Drug Design, Vol. 5. Elsevier Science; 2007. p 113-165.
39. Zhou S, Breitenbach JM, Borysko KZ, Drach JC, Kern ER, Gullen E, Cheng YC, Zemlicka J. Synthesis and antiviral activity of (Z)- and (E)-2, 2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: Second-generation methylenecyclopropane analogues of nucleosides. J Med Chem 2004;47:566-575.
40. Kern ER, Kushner NL, Hartline CB, Williams-Aziz SL, Harden EA, Zhou S, Zemlicka J, Prichard MN. In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother 2005;49:1039-1045.
41. Kern ER, Bidanset DJ, Hartline CB, Yan Z, Zemlicka J, Quenelle DC. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob Agents Chemother 2004;48:4745-4753.
42. Kern ER. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antiviral Res 2006;71:164-171.
43. De Clercq E, Naesens L. In search of effective anti-HHV-6 agents. J Clin Virol 2006;37(Suppl 1):S82-S86.
44. Wu Z, Drach JC, Prichard MN, Yanachkova M, Yanachkov I, Bowlin TL, Zemlicka J. L-valine ester of cyclopropavir: A new antiviral prodrug. Antivir Chem Chemother 2009;20:37-46.
45. Chou S, Bowlin TL. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob Agents Chemother 2011;55:382-384.
46. Gentry BG, Kamil JP, Coen DM, Zemlicka J, Drach JC. Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir. Antimicrob Agents Chemother 2010;54:3093-3098.
47. Gentry BG, Gentry SN, Jackson TL, Zemlicka J, Drach JC. Phosphorylation of antiviral and endogenous nucleotides to di- and triphosphates by guanosine monophosphate kinase. Biochem Pharmacol 2011;81:43-49.
48. Mhaske SB, Ksebati B, Prichard MN, Drach JC, Zemlicka J. Phosphonate analogues of cyclopropavir phosphates and their E-isomers. Synthesis and antiviral activity. Bioorg Med Chem 2009;17:3892-3899.
49. Marquez VE, Siddiqui MA, Ezzitouni A, Russ P, Wang J, Wagner RW, Matteucci MD. Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides? J Med Chem 1996;39:3739-3747.
50. Zalah L, Huleihel M, Manor E, Konson A, Ford H, Jr, Marquez VE, Johns DG, Agbaria R. Metabolic pathways of N-methanocarbathymidine, a novel antiviral agent, in native and herpes simplex virus type 1 infected Vero cells. Antiviral Res 2002;55:63-75.
51. Russ P, Schelling P, Scapozza L, Folkers G, De Clercq E, Marquez VE. Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. J Med Chem 2003;46:5045-5054.
52. Huleihel M, Talishanisky M, Ford H, Jr, Marquez VE, Kelley JA, Johns DG, Agbaria R. Dynamics of the antiviral activity of N-methanocarbathymidine against herpes simplex virus type 1 in cell culture. Int J Antimicrob Agents 2005;25:427-432.
53. Marquez VE, Ben-Kasus T, Barchi JJ, Jr, Green KM, Nicklaus MC, Agbaria R. Experimental and structural evidence that herpes 1 kinase and cellular DNA polymerase(s) discriminate on the basis of sugar pucker. J Am Chem Soc 2004;126:543-549.
54. Béres J, Sági G, Tömösközi I, Gruber L, Baitz-Gács E, Otvös L, De Clercq E. Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2′-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R, 5S)- and (-)-(1S, 5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one. J Med Chem 1990;33:1353-1360.
55. Prichard MN, Keith KA, Quenelle DC, Kern ER. Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections. Antimicrob Agents Chemother 2006;50:1336-1341.
56. Smee DF, Wandersee MK, Bailey KW, Wong MH, Chu CK, Gadthula S, Sidwell RW. Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice. Antiviral Res 2007;73:69-77.
57. Smee DF, Hurst BL, Wong MH, Glazer RI, Rahman A, Sidwell RW. Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus. Antiviral Res 2007;76:124-129.
58. Prichard MN, Kern ER, Quenelle DC, Keith KA, Moyer RW, Turner PC. Vaccinia virus lacking the deoxyuridine triphosphatase gene (F2L) replicates well in vitro and in vivo, but is hypersensitive to the antiviral drug (N)-methanocarbathymidine. Virol J 2008;5:39.
59. Zhu W, Burnette A, Dorjsuren D, Roberts PE, Huleihel M, Shoemaker RH, Marquez VE, Agbaria R, Sei S. Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus. Antimicrob Agents Chemother 2005;49:4965-4973.
60. Ludek OR, Marquez VE. A greener enantioselective synthesis of the antiviral agent North-methanocarbathymidine (N-MCT) from 2-deoxy-d-ribose. Tetrahedron 2009;65:8461-8467.
61. Comin MJ, Vu BC, Boyer PL, Liao C, Hughes SH, Marquez VE. D-(+)-iso-methanocarbathymidine: A high-affinity substrate for herpes simplex virus 1 thymidine kinase. ChemMedChem 2008;3:1129-1134.
62. Marquez VE, Hughes SH, Sei S, Agbaria R. The history of N-methanocarbathymidine: The investigation of a conformational concept leads to the discovery of a potent and selective nucleoside antiviral agent. Antiviral Res 2006;71:268-275.
63. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art. Antiviral Res 2009;82:A84-A98.
64. Quenelle DC, Lampert B, Collins DJ, Rice TL, Painter GR, Kern ER. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis 2010;202:1492-1499.
65. Bidanset DJ, Beadle JR, Wan WB, Hostetler KY, Kern ER. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis 2004;190:499-503.
66. Beadle JR, Hartline C, Aldern KA, Rodriguez N, Harden E, Kern ER, Hostetler KY. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002;46:2381-2386.
67. Kern ER, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Quenelle DC. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004;48:3516-3522.
68. Bravo FJ, Bernstein DI, Beadle JR, Hostetler KY, Cardin RD. Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection. Antimicrob Agents Chemother 2011;55:35-41.
69. Hartline CB, Gustin KM, Wan WB, Ciesla SL, Beadle JR, Hostetler KY, Kern ER. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: Activity against adenovirus replication in vitro. J Infect Dis 2005;191:396-399.
70. Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR, Wold WS. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 2008;105:7293-7297.
71. Paolino K, Sande J, Perez E, Loechelt B, Jantausch B, Painter W, Anderson M, Tippin T, Lanier ER, Fry T, DeBiasi RL. Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001. J Clin Virol 2011;50:167-170.
72. Andrei G, Snoeck R, Vandeputte M, De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997;41:587-593.
73. Bernhoff E, Gutteberg TJ, Sandvik K, Hirsch HH, Rinaldo CH. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant 2008;8:1413-1422.
74. Randhawa P, Farasati NA, Shapiro R, Hostetler KY. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother 2006;50:1564-1566.
75. Rinaldo CH, Gosert R, Bernhoff E, Finstad S, Hirsch HH. 1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob Agents Chemother 2010;54:4714-4722.
76. Jiang ZG, Cohen J, Marshall LJ, Major EO. Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures. Antimicrob Agents Chemother 2010;54:4723-4732.
77. Gosert R, Rinaldo CH, Wernli M, Major EO, Hirsch HH. CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes. Antimicrob Agents Chemother 2011;55:2129-2136.
78. Patel A, Patel J, Ikwuagwu J. Treatment of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother 2010;65:2489-2492.
79. Painter GR, Hostetler KY. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol 2004;22:423-427.
80. Kern ER, Hartline C, Harden E, Keith K, Rodriguez N, Beadle JR, Hostetler KY. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002;46:991-995.
81. Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Kern ER. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004;48:404-412.
82. Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004;318:474-481.
83. Parker S, Siddiqui AM, Oberle C, Hembrador E, Lanier R, Painter G, Robertson A, Buller RM. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies. Virology 2009;385:11-21.
84. Parker S, Siddiqui AM, Painter G, Schriewer J, Buller RM. Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics. Viruses 2010;2:1918-1932.
85. Parker S, Touchette E, Oberle C, Almond M, Robertson A, Trost LC, Lampert B, Painter G, Buller RM. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res 2008;77:39-49.
86. Parker S, Schriewer J, Oberle C, Robertson A, Lanier R, Painter G, Buller RM. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001. Antivir Ther 2008;13:863-873.
87. Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, Parker S. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. J Virol 2010;84:3909-3920.
88. Chen N, Bellone CJ, Schriewer J, Owens G, Fredrickson T, Parker S, Buller RM. Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis, and antiviral therapy. Virology 2011;409:328-337.
89. Rice AD, Adams MM, Wallace G, Burrage AM, Lindsey SF, Smith AJ, Swetnam D, Manning BR, Gray SA, Lampert B, Foster S, Lanier R, Robertson A, Painter G, Moyer RW. Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 2011;3:47-62.
90. Rice AD, Adams MM, Lampert B, Foster S, Lanier R, Robertson A, Painter G, Moyer RW. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 2001;3:63-82.
91. Lanier R, Trost L, Tippin T, Lampert B, Robertson A, Foster S, Rose M, Painter W, OMahony R, Almond M, Painter G. Development of CMX001 for the treatment of poxvirus infections. Viruses 2010;2:2740-2762.
92. Wan WB, Beadle JR, Hartline C, Kern ER, Ciesla SL, Valiaeva N, Hostetler KY. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother 2005;49:656-662.
93. Ruiz J, Beadle JR, Buller RM, Schreiwer J, Prichard MN, Keith KA, Lewis KC, Hostetler KY. Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine. Bioorg Med Chem 2011;19:2950-2958.
94. Buys KK, Jung KH, Smee DF, Furuta Y, Gowen BB. Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir. Antivir Chem Chemother 2011;21:193-200.
95. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002;46:977-981.
96. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005;49:981-986.
97. Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother 2009;64:741-746.
98. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 2010;107:882-887.
99. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, Morrey JD, Furuta Y. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007;51:845-851.
100. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 2010;54:2517-2524.
101. Smee DF, Hurst BL, Wong MH, Bailey KW, Tarbet EB, Morrey JD, Furuta Y. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 2010;54:126-133.
102. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009;82:95-102.
103. Julander JG, Furuta Y, Shafer K, Sidwell RW. Activity of T-1106 in a hamster model of yellow fever virus infection. Antimicrob Agents Chemother 2007;51:1962-1966.
104. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 2009;53:202-209.
105. Morrey JD, Taro BS, Siddharthan V, Wang H, Smee DF, Christensen AJ, Furuta Y. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 2008;80:377-379.
106. Julander JG, Smee DF, Morrey JD, Furuta Y. Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res 2009;82:169-171.
107. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007;51:3168-3176.
108. Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, Holbrook MR, Furuta Y, de la Torre JC, Nunberg JH, Gowen BB. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother 2011;55:782-787.
109. Gowen BB, Smee DF, Wong MH, Hall JO, Jung KH, Bailey KW, Stevens JR, Furuta Y, Morrey JD. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 2008;3:e3725.
110. Gowen BB, Wong MH, Jung KH, Smee DF, Morrey JD, Furuta Y. Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res 2010;86:121-127.
111. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986;314:20-26.
112. Moreno H, Gallego I, Sevilla N, de la Torre JC, Domingo E, Martín V. Ribavirin can be mutagenic for arenaviruses. J Virol 2011;85:7246-7255.
113. Lee AM, Pasquato A, Kunz S. Novel approaches in anti-arenaviral drug development. Virology 2011;411:163-169.
114. Charrel RN, Coutard B, Baronti C, Canard B, Nougairede A, Frangeul A, Morin B, Jamal S, Schmidt CL, Hilgenfeld R, Klempa B, de Lamballerie X. Arenaviruses and hantaviruses: From epidemiology and genomics to antivirals. Antiviral Res 2011;90:102-114.
115. Gowen BB, Wong MH, Larson D, Ye W, Jung KH, Sefing EJ, Skirpstunas R, Smee DF, Morrey JD, Schneller SW. Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog. PLoS One 2010;5:e12760.
116. Barradas JS, Errea MI, DAccorso NB, Sepúlveda CS, Damonte EB. Imidazo[2, 1-b]thiazole carbohydrate derivatives: Synthesis and antiviral activity against Junin virus, agent of Argentine hemorrhagic fever. Eur J Med Chem 2011;46:259-264.
117. Müller S, Günther S. Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus. Antimicrob Agents Chemother 2007;51:2215-2218.
118. Asper M, Sternsdorf T, Hass M, Drosten C, Rhode A, Schmitz H, Günther S. Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J Virol 2004;78:3162-3169.
119. Albiol Matanic VC, Castilla V. Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int J Antimicrob Agents 2004;23:382-389.
120. Radoshitzky SR, Dong L, Chi X, Clester JC, Retterer C, Spurgers K, Kuhn JH, Sandwick S, Ruthel G, Kota K, Boltz D, Warren T, Kranzusch PJ, Whelan SP, Bavari S. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J Virol 2010;84:10569-10580.
121. Qi X, Lan S, Wang W, Schelde LM, Dong H, Wallat GD, Ly H, Liang Y, Dong C. Cap binding and immune evasion revealed by Lassa nucleoprotein structure. Nature 2010;468:779-783.
122. Emonet SE, Urata S, de la Torre JC. Arenavirus reverse genetics: New approaches for the investigation of arenavirus biology and development of antiviral strategies. Virology 2011;411:416-425.
123. Hawkins JL, Robbins MD, Warren LC, Xia D, Petras SF, Valentine JJ, Varghese AH, Wang IK, Subashi TA, Shelly LD, Hay BA, Landschulz KT, Geoghegan KF, Harwood HJ, Jr. Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. J Pharmacol Exp Ther 2008;326:801-808.
124. Hay BA, Abrams B, Zumbrunn AY, Valentine JJ, Warren LC, Petras SF, Shelly LD, Xia A, Varghese AH, Hawkins JL, Van Camp JA, Robbins MD, Landschulz K, Harwood HJ, Jr. Aminopyrrolidineamide inhibitors of site-1 protease. Bioorg Med Chem Lett 2007;17:4411-4414.
125. Urata S, Yun N, Pasquato A, Paessler S, Kunz S, de la Torre JC. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J Virol 2011;85:795-803.
126. Bolken TC, Laquerre S, Zhang Y, Bailey TR, Pevear DC, Kickner SS, Sperzel LE, Jones KF, Warren TK, Amanda Lund S, Kirkwood-Watts DL, King DS, Shurtleff AC, Guttieri MC, Deng Y, Bleam M, Hruby DE. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res 2006;69:86-97.
127. Lee AM, Rojek JM, Spiropoulou CF, Gundersen AT, Jin W, Shaginian A, York J, Nunberg JH, Boger DL, Oldstone MB, Kunz S. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J Biol Chem 2008;283:18734-18742.
128. Thomas CJ, Casquilho-Gray HE, York J, DeCamp DL, Dai D, Petrilli EB, Boger DL, Slayden RA, Amberg SM, Sprang SR, Nunberg JH. A specific interaction of small molecule entry inhibitors with the envelope glycoprotein complex of the Junín hemorrhagic fever arenavirus. J Biol Chem 2011;286:6192-6200.
129. York J, Dai D, Amberg SM, Nunberg JH. pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J Virol 2008;82:10932-10939.
130. Larson RA, Dai D, Hosack VT, Tan Y, Bolken TC, Hruby DE, Amberg SM. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol 2008;82:10768-10775.
131. Barnard DL. Current status of anti-picornavirus therapies. Curr Pharm Des 2006;12:1379-1390.
132. Diana GD, Rudewicz P, Pevear DC, Nitz TJ, Aldous SC, Aldous DJ, Robinson DT, Draper T, Dutko FJ, Aldi C. Picornavirus inhibitors: Trifluoromethyl substitution provides a global protective effect against hepatic metabolism. J Med Chem 1995;38:1355-1371.
133. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 1999;43:2109-2115.
134. Rotbart HA, Webster AD. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin. Infect. Dis. 2001;32:228-235.
135. Senior K. FDA panel rejects common cold treatment. Lancet Infect Dis 2002;2:264.
136. Abzug MJ, Cloud G, Bradley J, Sánchez PJ, Romero J, Powell D, Lepow M, Mani C, Capparelli EV, Blount S, Lakeman F, Whitley RJ, Kimberlin DW; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J 2003;22:335-341.
137. Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, Liu S, Hudson S, Pevear DC, Collett M, McKinlay M; Pleconaril Respiratory Infection Study Group. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003;36:1523-1532.
138. Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother 2005;49:4492-4499.
139. De Palma AM, Vliegen I, De Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Med Res Rev 2008;28:823-884.
140. Desmond RA, Accortt NA, Talley L, Villano SA, Soong SJ, Whitley RJ. Enteroviral meningitis: Natural history and outcome of pleconaril therapy. Antimicrob Agents Chemother 2006;50:2409-2414.
141. van de Ven AA, Douma JW, Rademaker C, van Loon AM, Wensing AM, Boelens JJ, Sanders EA, van Montfrans JM. Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia. Antivir Ther 2011;16:611-614.
142. Schmidtke M, Wutzler P, Zieger R, Riabova OB, Makarov VA. New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3. Antiviral Res 2009;81:56-63.
143. Cheng J, Xie J, Luo X. Synthesis and antiviral activity against Coxsackie virus B3 of some novel benzimidazole derivatives. Bioorg Med Chem Lett 2005;15:267-269.
144. Ahn J, Jun ES, Lee HS, Yoon SY, Kim D, Joo CH, Kim YK, Lee H. A small interfering RNA targeting coxsackievirus B3 protects permissive HeLa cells from viral challenge. J Virol 2005;79:8620-8624.
145. Werk D, Pinkert S, Heim A, Zeichhardt H, Grunert HP, Poller W, Erdmann VA, Fechner H, Kurreck J. Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3. Antiviral Res 2009;83:298-306.
146. Aguado L, Thibaut HJ, Priego EM, Jimeno ML, Camarasa MJ, Neyts J, Pérez-Pérez MJ. 9-Arylpurines as a novel class of enterovirus inhibitors. J Med Chem 2010;53:316-324.
147. Padalko E, Verbeken E, Matthys P, Aerts JL, De Clercq E, Neyts J. Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice. BMC Microbiol 2003;3:25.
148. Padalko E, Verbeken E, De Clercq E, Neyts J. Inhibition of coxsackie B3 virus induced myocarditis in mice by 2-(3, 4-dichlorophenoxy)-5-nitrobenzonitrile. J Med Virol 2004;72:263-267.
149. Padalko E, Nuyens D, De Palma A, Verbeken E, Aerts JL, De Clercq E, Carmeliet P, Neyts J. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother 2004;48:267-274.
150. Thibaut HJ, Leyssen P, Puerstinger G, Muigg A, Neyts J, De Palma AM. Towards the design of combination therapy for the treatment of enterovirus infections. Antiviral Res 2011;90:213-217.
151. De Palma AM, Heggermont W, Lanke K, Coutard B, Bergmann M, Monforte AM, Canard B, De Clercq E, Chimirri A, Pürstinger G, Rohayem J, van Kuppeveld F, Neyts J. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J Virol 2008;82:4720-4730.
152. De Palma AM, Pürstinger G, Wimmer E, Patick AK, Andries K, Rombaut B, De Clercq E, Neyts J. Potential use of antiviral agents in polio eradication. Emerg Infect Dis 2008;14:545-551.
153. Norder H, De Palma AM, Selisko B, Costenaro L, Papageorgiou N, Arnan C, Coutard B, Lantez V, De Lamballerie X, Baronti C, Solà M, Tan J, Neyts J, Canard B, Coll M, Gorbalenya AE, Hilgenfeld R. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res 2011;89:204-218.
154. Su M, Li Y, Leung KT, Cen Y, Li T, Chen R, Ooi VE. Antiviral activity and constituent of Ardisia chinensis benth against coxsackie B3 virus. Phytother Res 2006;20:634-639.
155. Li Y, But PP, Ooi VE. Antiviral activity and mode of action of caffeoylquinic acids from Schefflera heptaphylla (L.) Frodin. Antiviral Res 2005;68:1-9.
156. Liu Q, Wang YF, Chen RJ, Zhang MY, Wang YF, Yang CR, Zhang YJ. Anti-coxsackie virus B3 norsesquiterpenoids from the roots of Phyllanthus emblica. J Nat Prod 2009;72:969-972.
157. Li Y, Jiang R, Ooi LS, But PP, Ooi VE. Antiviral triterpenoids from the medicinal plant Schefflera heptaphylla. Phytother Res 2007;21:466-470.
158. Zhu H, Zhang Y, Ye G, Li Z, Zhou P, Huang C. In vivo and in vitro antiviral activities of calycosin-7-O-beta-D-glucopyranoside against coxsackie virus B3. Biol Pharm Bull 2009;32:68-73.
159. Li Y, Leung KT, Yao F, Ooi LS, Ooi VE. Antiviral flavans from the leaves of Pithecellobium clypearia. J Nat Prod 2006;69:833-835.
160. Tait S, Salvati AL, Desideri N, Fiore L. Antiviral activity of substituted homoisoflavonoids on enteroviruses. Antiviral Res 2006;72:252-255.
161. Sakai A, Watanabe K, Koketsu M, Akuzawa K, Yamada R, Li Z, Sadanari H, Matsubara K, Muroyama T. Anti-human cytomegalovirus activity of constituents from Sasa albo-marginata (Kumazasa in Japan). Antivir Chem Chemother 2008;19:125-132.
162. Yazawa K, Tsuchida Y, Yamada R, Sadanari H, Murayama T. Anti-influenza virus activity by tricin, isolated from Sasa Albo-marginata in Japan. The Twenty-Third International Conference on Antiviral Research, San Francisco, CA, 25-28 April 2010. Antiviral Res 2010; 86:A49, abstract no 108.
163. Ninomiya M, Tanaka K, Tsuchida Y, Muto Y, Koketsu M, Watanabe K. Increased bioavailability of tricin-amino acid derivatives via a prodrug approach. J Med Chem 2011;54:1529-1536.
164. Ogawara H, Akiyama T, Ishida J, Watanabe S, Suzuki K. A specific inhibitor for tyrosine protein kinase from Pseudomonas. J Antibiot 1986;39:606-608.
165. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5595.
166. Vela EM, Bowick GC, Herzog NK, Aronson JF. Genistein treatment of cells inhibits arenavirus infection. Antiviral Res 2008;77:153-156.
167. Vela EM, Zhang L, Colpitts TM, Davey RA, Aronson JF. Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism. Virology 2007;369:1-11.
168. Vela EM, Knostman KA, Mott JM, Warren RL, Garver JN, Vela LJ, Stammen RL. Genistein, a general kinase inhibitor, as a potential antiviral for arenaviral hemorrhagic fever as described in the Pirital virus-Syrian golden hamster model. Antiviral Res 2010;87:318-328.
169. Choi HJ, Lim CH, Song JH, Baek SH, Kwon DH. Antiviral activity of raoulic acid from Raoulia australis against Picornaviruses. Phytomedicine 2009;16:35-39.
170. Pollara JJ, Laster SM, Petty IT. Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid. Antiviral Res 2010;88:287-295.
171. Myskiw C, Piper J, Huzarewich R, Booth TF, Cao J, He R. Nigericin is a potent inhibitor of the early stage of vaccinia virus replication. Antiviral Res 2010;88:304-310.
172. Alonso-Caplen FV, Compans RW. Modulation of glycosylation and transport of viral membrane glycoproteins by a sodium ionophore. J Cell Biol 1983;97:659-668.
173. Irurzun A, Sánchez-Palomino S, Novoa I, Carrasco L. Monensin and nigericin prevent the inhibition of host translation by poliovirus, without affecting p220 cleavage. J Virol 1995;69:7453-7460.
174. Naesens L, Vanderlinden E, Roth E, Jeko J, Andrei G, Snoeck R, Pannecouque C, Illyés E, Batta G, Herczegh P, Sztaricskai F. Anti-influenza virus activity and structure-activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains. Antiviral Res 2009;82:89-94.
175. Balzarini J, Pannecouque C, De Clercq E, Pavlov AY, Printsevskaya SS, Miroshnikova OV, Reznikova MI, Preobrazhenskaya MN. Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics. J Med Chem 2003;46:2755-2764.
176. Balzarini J, Keyaerts E, Vijgen L, Egberink H, De Clercq E, Van Ranst M, Printsevskaya SS, Olsufyeva EN, Solovieva SE, Preobrazhenskaya MN. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res 2006;72:20-33.
177. Wachsman MB, López EM, Ramirez JA, Galagovsky LR, Coto CE. Antiviral effect of brassinosteroids against herpes virus and arenaviruses. Antivir Chem Chemother 2000;11:71-77.
178. Wachsman MB, Ramirez JA, Galagovsky LR, Coto CE. Antiviral activity of brassinosteroids derivatives against measles virus in cell cultures. Antivir Chem Chemother 2002;13:61-66.
179. Castilla V, Larzábal M, Sgalippa NA, Wachsman MB, Coto CE. Antiviral mode of action of a synthetic brassinosteroid against Junin virus replication. Antiviral Res 2005;68:88-95.
180. Tanaka N, Okasaka M, Ishimaru Y, Takaishi Y, Sato M, Okamoto M, Oshikawa T, Ahmed SU, Consentino LM, Lee KH. Biyouyanagin A, an anti-HIV agent from Hypericum chinense L. var. salicifolium. Org Lett 2005;7:2997-2999.
181. Nicolaou KC, Sanchini S, Sarlah D, Lu G, Wu TR, Nomura DK, Cravatt BF, Cubitt B, de la Torre JC, Hessell AJ, Burton DR. Design, synthesis, and biological evaluation of a biyouyanagin compound library. Proc Natl Acad Sci USA 2011;108:6715-6720.
182. Droebner K, Pleschka S, Ludwig S, Planz O. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res 2011;92:195-203.
183. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23:5281-5293.
184. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16:2450-2457.
185. Pinto R, Herold S, Cakarova L, Hoegner K, Lohmeyer J, Planz O, Pleschka S. Inhibition of influenza virus-induced NF-kappaB and Raf-MEK-ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. Antiviral Res 2011, 92:45-56.
186. Ludwig S, Wolff T, Ehrhardt C, Wurzer WJ, Reinhardt J, Planz O, Pleschka S. MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett 2004;561:37-43.
187. Ludwig S, Ehrhardt C, Neumeier ER, Kracht M, Rapp UR, Pleschka S. Influenza virus-induced AP-1-dependent gene expression requires activation of the JNK signaling pathway. J Biol Chem 2001;276:10990-10998.
188. Kujime K, Hashimoto S, Gon Y, Shimizu K, Horie T. p38 mitogen-activated protein kinase and c-jun-NH2-terminal kinase regulate RANTES production by influenza virus-infected human bronchial epithelial cells. J Immunol 2000;164:3222-3228.
189. Pleschka S, Wolff T, Ehrhardt C, Hobom G, Planz O, Rapp UR, Ludwig S. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol 2001;3:301-305.
190. Jacqué JM, Mann A, Enslen H, Sharova N, Brichacek B, Davis RJ, Stevenson M. Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase. EMBO J 1998;17:2607-2618.
191. Popik W, Pitha PM. Inhibition of CD3/CD28-mediated activation of the MEK/ERK signaling pathway represses replication of X4 but not R5 human immunodeficiency virus type 1 in peripheral blood CD4(+) T lymphocytes. J Virol 2000;74:2558-2566.
192. Luo H, Yanagawa B, Zhang J, Luo Z, Zhang M, Esfandiarei M, Carthy C, Wilson JE, Yang D, McManus BM. Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J Virol 2002;76:3365-3373.
193. Cai Y, Liu Y, Zhang X. Suppression of coronavirus replication by inhibition of the MEK signaling pathway. J Virol 2007;81:446-456.
194. Zhang H, Feng H, Luo L, Zhou Q, Luo Z, Peng Y. Distinct effects of knocking down MEK1 and MEK2 on replication of herpes simplex virus type 2. Virus Res 2010;150:22-27.
195. Planz O, Pleschka S, Ludwig S. MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells. J Virol 2001;75:4871-4877.
196. Shyu HW, Lin YY, Chen LC, Wang YF, Yeh TM, Su SJ, Cheng WC, Chen CY, Lin KH, Chou MC. he dengue virus envelope protein induced PAI-1 gene expression via MEK/ERK pathways. Thromb Haemost 2010;104:1219-1227.
197. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-27494.
198. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;92:7686-7689.
199. Barber SA, Bruett L, Douglass BR, Herbst DS, Zink MC, Clements JE. Visna virus-induced activation of MAPK is required for virus replication and correlates with virus-induced neuropathology. J Virol 2002;76:817-828.
200. Michaelis M, Paulus C, Löschmann N, Dauth S, Stange E, Doerr HW, Nevels M, Cinatl J, Jr. The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. Cell Mol Life Sci 2011;68:1079-1090.
201. Soroceanu L, Akhavan A, Cobbs CS. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 2008;455:391-395.
202. Schleiss M, Eickhoff J, Auerochs S, Leis M, Abele S, Rechter S, Choi Y, Anderson J, Scott G, Rawlinson W, Michel D, Ensminger S, Klebl B, Stamminger T, Marschall M. Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo. Antiviral Res 2008;79:49-61.
203. Rodems SM, Spector DH. Extracellular signal-regulated kinase activity is sustained early during human cytomegalovirus infection. J Virol 1998;72:9173-9180.
204. Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, Hong PW, Li J, Watson NF, Fang AQ, Aguilar HC, Porotto M, Honko AN, Damoiseaux R, Miller JP, Woodson SE, Chantasirivisal S, Fontanes V, Negrete OA, Krogstad P, Dasgupta A, Moscona A, Hensley LE, Whelan SP, Faull KF, Holbrook MR, Jung ME, Lee B. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci USA 2010;107:3157-3162.
205. St Vincent MR, Colpitts CC, Ustinov AV, Muqadas M, Joyce MA, Barsby NL, Epand RF, Epand RM, Khramyshev SA, Valueva OA, Korshun VA, Tyrrell DL, Schang LM. Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci USA 2010;107:17339-17344.